Pyroptosis is an inflammatory caspase-induced lytic cell death. The normal operation of pyroptosis requires the regulation of many specific proteins, such as the inflammasome and gasdermin protein family. The occurrence of pyroptosis triggers an inflammatory response, oxidative stress, and other pathological processes that exacerbate the damage to brain tissue in the stroke. Therefore, targeting these specific proteins to inhibit pyroptosis and thus achieve stroke treatment is a potential therapeutic way. Ace Therapeutics provides a complete service to develop therapeutic agents for stroke targeting specific proteins in pyroptosis.
It has been shown that NLRP1 inflammasome, NLRP3 inflammasome, AIM2 inflammasome, NLRC4 inflammasome, and gasdermin protein family are all specific proteins in the process of pyroptosis. However, since the current understanding of pyroptosis is limited, we still need to discover more targets to better serve the development of stroke drugs targeting pyroptosis.
After screening for potential targets of pyroptosis in stroke, a high-throughput screen for inhibitors against these targets was performed to identify drugs with potential therapeutic activity against stroke. Thus, Ace Therapeutics provides a platform for high-throughput screening against pyroptosis inhibitors, as well as experimental models of pyroptosis to validate the effects of candidate inhibitors.
We have demonstrated the inhibition of pyroptosis by candidate pyroptosis inhibitors. Immediately after, we offer various pharmacological activity assessment services to test the efficacy of candidate pyroptosis inhibitors against stroke.
If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.